ERBB2 and neoplasm: As previously reported (Rivera et al, 2003; Fabi et al, 2006), the overall response rate in our study did not vary according to previous exposure to anthracyclines or disease sites, whereas it was significantly higher in cases whose tumours overexpress erbB2/neu, as compared with erbB2/neu-negative cases.